QSAM Biosciences Прибыль на акцию Q/Q

Что обозначает Прибыль на акцию Q/Q в QSAM Biosciences?

Прибыль на акцию Q/Q QSAM Biosciences, Inc. является N/A

Какое определение для Прибыль на акцию Q/Q?



Ежеквартальный темп роста прибыли на акцию, по сравнению с предыдущим кварталом, представляет собой увеличение прибыли на акцию компании за последние 4 квартала по сравнению с показателями за предыдущие 4 квартала.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Что делает QSAM Biosciences?

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.